Poster BT-001Marchand, Semmrich, Fend et al. Immuno-Oncology summit Download the poster here Poster Presentation
Catégorie : Publication
Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Poster 0710-AASLD 2019-TG1050-T101_MetaanalyseFabien Zoulim et al.AASLD 2019Download the poster herePoster Presentation
Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Transgene SITC 2019 PosterJean-Baptiste Marchand et al.SITC 2019Download the poster herePoster Presentation
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al.ESMO 2019Download the poster herePoster Presentation
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al.ESMO 2019Download the poster herePoster Presentation
The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Diane. M. Harper, et al.Gynecologic Oncology, April 2019 – Download the articleThe publication has been featured in The Lancet Oncology and Medpage TodayPublication
The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Diane M. Harper, et al.Gynecologic Oncology, April 2019 – Download the articleThe publication has been featured in The Lancet Oncology and Medpage TodayPublication
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Johann Foloppe, et al.Molecular Therapy Oncolytics, March 2019 – Download the articlePublication
Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Roland Kratzer, et al. AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website Download the poster here Poster Presentation Collaboration between Transgene – Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France – Université Paris Diderot, Sorbonne Paris Cité, Paris, France – Hôpital Saint-Louis, Assistance Publique-Hôpitaux… Poursuivre la lecture Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice